Zbigniew Rudzki

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Timothy P. Hughes, Jaspal Kaeda, Susan Branford et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

Life Sciences, Hematology, Oncology +13

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 771 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +9

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2002 · 657 citations · Full text

Medicine, Hematology, Molecular Genetics +14

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C.P. Cross et al. · Blood · 2008 · 389 citations · Full text

Medicine, Biostatistics, Performance Measurement +9

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

Victoria Weston, Ceri Oldreive, Anna Skowrońska et al. · Blood · 2010 · 305 citations · Full text

Medicine, Oncology, Pharmacology +9